Return of alosetron.
Hyman
Paul E
PE
Garvey
Thomas Q
TQ
D000293:Adolescent; D000328:Adult; D002243:Carbolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000503:physiopathology; D017277:Drug Approval; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron